Navigation Links
EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
Date:11/28/2007

TARRYTOWN, N.Y., Nov. 28 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley, President and CEO, will present a company overview at the BMO Capital Markets Focus on Healthcare Conference on December 5, 2007 at 11:00 a.m. Eastern Time. The conference will be held at The Millennium Broadway Hotel in New York City on December 4th and 5th. Mr. Talley will present a company overview.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

The presentation will be available live via webcast on December 5, 2007. The webcast can be accessed by visiting the Company's website at http://www.epicept.com. A replay of the presentation will be available following the event.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that EpiCept will not receive any significant payments under its agreement with Myriad, the risk that the development of the Company's other apoptosis product candidates will not be successful, the risk that its ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that the Company's other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of its product candidates; the cost, delays and uncertainties associated with its scientific research, product development, clinical trials and regulatory approval process; its history of operating losses since inception; competition; litigation; risks associated with prior material weaknesses in internal controls; and risks associated with the Company's ability to protect its intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at http://www.sec.gov or at http://www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCT-GEN

*Azixa is a registered trademark of Myriad Genetics, Inc.


'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
7. Brooke Franchise Corporation Announces Selected July Results
8. MedThink Communications Retained by NanoBio Corporation
9. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
10. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... The ... Waikiki Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity ... management. , The demand for supplemental training related to pain management has ...
(Date:12/2/2016)... ... 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique ... other wearable health technology on the market can deliver all that rejiva can. , ... insights about their health than the usual heart rate and steps taken”, adds Evens ...
(Date:12/2/2016)... ... 02, 2016 , ... Clarify Health Solutions, Inc., the leading ... in an initial round of funding. The round was led by experienced investors ... receive far better care through the application of the best technologies from other ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health radio ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 bioLytical Laboratories, ein Weltführer bei ... den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical ...
(Date:12/2/2016)... Orthopedic Implants (Including Spinal Implants, Reconstructive Joint Implants, ... Significant Market Share Owing to a Large Global Baby Boomer ... ... According to a new report by Persistence Market Research titled ... Type Segment Projected to Witness a Significantly High CAGR Through ...
(Date:12/2/2016)... , December 2, 2016 On ... trading session in red, while the Dow Jones Industrial Average ... the close of US markets, which prompted Stock-callers this morning ... NuVasive Inc. (NASDAQ: NUVA ), Smith & Nephew ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology: